Page 2 - Safety Study News Today

Additional indication for pediatric patients with severe eosinophilic asthma ...

Workplace Options (WPO) Debuts Data-Driven Study Across 9 Nations; Explores Workplace Issues, Need for Inclusive Leadership, and Renewed Commitment...

The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.

Workplace Options presents first global study on how psychological safety affects employees in nine nations utilizing data from WPO clinicians-no surveys....

Vadadustat (Vafseo; Akebia Therapeutics Inc) is indicated for individuals with chronic kidney disease who have been receiving dialysis for at least 3 months.

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here.

A0626i FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+ NMOSD the potential to live relapse-free Unprecedented relapse risk reduction observed in CHAMPION-NMOSD trial...

Zero relapses were reported among individuals that received ravulizumab-cwvz over the 73 weeks of treatment.

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Feb 27, 2024--